Our Journey

AFRICAN WOMEN PREVENTION COMMUNITY ACCOUNTABILITY BOARD (AWPCAB)

The board is composed of 14 women from 7 countries representing both East and Southern African nations. The main focus of the website is to ensure the choice agenda/ manifesto is easily accessible in order for it to be a reality to all women once it is rolled out.

  • 2010:

    Advocating for Contraceptive Options and choices – the first Global CAB, ECHO trial and options and choice agenda in the ECHO Trial and recommendations

  • 2016 Dec:

    HPTN 084 consultation and pre-meeting with advocates on trial design and plans

  • 2017: Aug:

    HPTN 084 consultation to review the study plans and build partnerships

  • 2018:

    Advocates tracked the trial hold on HPTN 084 following data on NTD related to DTG, which is in the same class of drugs as CAB

  • 2019:

    Advocates continue to follow the enrollment and conduct of trials

  • 2020:

    • March: HPTN publishes and presents trial data, noting the presence of ‘masked infections’ and testing considerations. Advocates break down trial results (e.g. conferences sessions, webinars, materials and briefs, etc.)
    • May: HPTN 083 early efficacy data
    • Mid to late-2020: Planned communications & advocacy around result scenarios for HPTN 084 results, ensuring options for women remain a priority; engaged in consultations /webinars around key issues; updated materials
    • November: HPTN 084 early efficacy data

  • 2021:

    Advocates prepare for introduction of CAB for PrEP; other projects (BioPIC, MOSAIC, ViiV) focused on introduction kick into high gear
    • WHO/AVAC Think Tanks on implementation studies and HIV testing, with active participation of advocates

  • 2022:

    March: Advocates participate in WHO Guideline Development Group, and release statements with demands around cost and manufacturing March/April: ViiV meets with African women’s health advocates in South Africa, leading to the establishment of the African Women Community Prevention Accountability Board and subsequent bi-monthly meetings May: Workshops, think tanks (e.g. BioPIC), and consultations continue with CS June: Advocates meet with UNAIDS to discuss the choice agenda; publication of Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP; HPTN meeting with updates on OLE July: ViiV/KP Advisory Group consultation; AIDS 2022: launch of Coalition to Accelerate Access to Long-Acting PrEP, and announcement of voluntary license between MPP/ViiV, data from 083 (TG populations) and 084 Aug - Dec: CS involvement and leadership in implementation studies (linked with MOSAIC), BioPIC think tanks, CAB for PrEP Teach-in series, Coalition to Accelerate Access to Long-Acting PrEP CS caucus, AfroCAB working groups, etc.

  • 2023:

    Jan/Feb: Advocates await updates from MPP on the selection of generics while continuing to engage with ViiV, provide input into implementation studies, and engage with national governments around registration for and rollout of CAB for PrEP Feb: Preliminary findings that show protective levels with quarterly injections are presented at CROI IWD2024 “ We celebrate African women in the Fight to end New HIV infections May: Let Women LEAD – Interest Conference Mozambique September Launch of the Choice Manifesto in Kampala Uganda, endorsed by Ms Winnie Byanyima UNAIDS Executive Director with regional Women's groups

Our Presences

The board is composed of 12 women from 7 countries representing both East and Southern African nations. The main focus of the website is to ensure the choice agenda/ manifesto is easily accessible in order for it to be a reality to all women once it is rolled out.

  1. Kenya

  2. Tanzania

  3. Uganda

  4. South Africa

  5. Zimbabwe

  6. Zambia

  7. Malawi

  8. Rwanda